id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-E-0114-0008,FDA,FDA-2011-E-0114,U.S. Patent and Trademark Office to Novo Nordisk Cerificate Extending Patent Term,Other,Certificate Extending Patent Term,2013-12-05T05:00:00Z,2013,12,2013-12-05T05:00:00Z,,2013-12-05T19:19:52Z,,0,0,09000064814a8f86
FDA-2011-E-0114-0007,FDA,FDA-2011-E-0114,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2012-12-27T05:00:00Z,2012,12,2012-12-27T05:00:00Z,,2024-03-13T11:58:33Z,,0,0,090000648119c7dd
FDA-2011-E-0114-0006,FDA,FDA-2011-E-0114,Determination of Patent Extension Regulatory Review Period; Victoza,Notice,General Notice,2012-05-02T04:00:00Z,2012,5,2012-05-02T04:00:00Z,2012-07-03T03:59:59Z,2012-05-02T20:09:15Z,2012-10517,0,0,09000064810033cc
FDA-2011-E-0114-0005,FDA,FDA-2011-E-0114,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2012-04-17T04:00:00Z,2012,4,2012-04-17T04:00:00Z,,2024-03-13T11:58:17Z,,0,0,0900006480ff2a5f
FDA-2011-E-0114-0004,FDA,FDA-2011-E-0114,Letter to U. S. Patent & Trademark Office,Other,Letter(s),2012-01-10T05:00:00Z,2012,1,2012-01-10T05:00:00Z,,2024-03-13T17:30:18Z,,0,0,0900006480f91f90
FDA-2011-E-0114-0003,FDA,FDA-2011-E-0114,FDA/CDER to U.S. Patent and Trademari Office - Letter,Other,LET-Letter,2011-04-25T04:00:00Z,2011,4,2011-04-25T04:00:00Z,,2011-04-25T19:24:53Z,,0,0,0900006480c37dcb
FDA-2011-E-0114-0002,FDA,FDA-2011-E-0114,U.S. Patent and Trademark Office - Letter,Other,LET-Letter,2011-02-25T05:00:00Z,2011,2,2011-02-25T05:00:00Z,,2013-07-27T23:46:05Z,,0,0,0900006480bf83ed
FDA-2011-E-0114-0001,FDA,FDA-2011-E-0114,"Novo Nordisk A/S c/o Novo Nordisk, Inc. (Richard W. Bork) - Patent Term Extension Application",Other,APP-Application,2011-02-25T05:00:00Z,2011,2,2011-02-25T05:00:00Z,,2013-07-27T23:46:04Z,,0,0,0900006480bf7cf5